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Flora Tassone1,2, Paul J Hagerman1,2 and Randi J Hagerman2,3*Abstract
Whereas full mutation CGG-repeat expansions (>200 repeats) of the fragile X gene (FMR1) give rise to the
neurodevelopmental disorder, fragile X syndrome (FXS); smaller, ‘premutation’ expansions (55 to 200 repeats) are now
gaining increasing recognition as the basis for a spectrum of clinical involvement, from neurodevelopmental
problems; to mid-adult disorders, such as primary ovarian insufficiency and mood and psychiatric disorders;
to the late-adult-onset neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS). The
premutation disorders are thought to arise through a molecular mechanism involving toxicity of the elevated
levels of expanded CGG-repeat mRNA (‘RNA toxicity’), a process that is entirely distinct from the FMR1 protein-deficiency
that gives rise to FXS. However, despite the importance of the spectrum of clinical disorders associated with the
premutation, and a high prevalence rate (1 in 130 to 250 females and 1 in 250 to 810 males), relatively little
attention has been paid to these disorders and there is a general lack of awareness among clinicians as to
the distinction between the premutation disorders and FXS. To address this lack of awareness, an international
conference on the premutation was held in Perugia, Italy, in June 2013. The conference covered the expanding range
of clinical involvement, refinements of the assessments and tools for characterizing such involvement, and the rapidly
expanding understanding of the pathogenic molecular and cellular mechanisms that give rise to the spectrum of
involvement among premutation carriers. All of these advances support ongoing efforts to develop new targeted
treatments for the premutation disorders. As an outgrowth of the meeting, papers were solicited from the conference
attendees such that groups of scientists and clinicians would develop works that broadly covered the topics of the
meeting. The following papers represent that effort.Introduction
Whereas full mutation CGG-repeat expansions (>200 re-
peats) of the fragile X gene (FMR1) give rise to the neuro-
developmental disorder, fragile X syndrome (FXS); smaller,
‘premutation’ expansions (55 to 200 repeats) are now gain-
ing increasing recognition as the basis for a spectrum of
clinical involvement, from neurodevelopmental problems,
to mid-adult disorders, such as the fragile X-associated
primary ovarian insufficiency (FXPOI) and mood and
psychiatric disorders, to the late-adult-onset neurodegen-
erative disorder, fragile X-associated tremor/ataxia syn-
drome (FXTAS). The premutation disorders are thought
to arise through a molecular mechanism involving toxicity
of the elevated levels of expanded CGG-repeat mRNA
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unless otherwise stated.FMR1 protein-deficiency that gives rise to FXS. However,
despite the importance of the spectrum of clinical disor-
ders associated with the premutation, and a high preva-
lence rate (1 in 130 to 250 females and 1 in 250 to 810
males), relatively little attention has been paid to these dis-
orders and there is a general lack of awareness among cli-
nicians as to the distinction between the premutation
disorders and FXS. To address this lack of awareness, an
international conference on the premutation was held in
Perugia, Italy, in June 2013. The conference covered the
expanding range of clinical involvement, refinements of
the assessments and tools for characterizing such involve-
ment, and the rapidly expanding understanding of the
pathogenic molecular and cellular mechanisms that give
rise to the spectrum of involvement among premutation
carriers. All of these advances support ongoing efforts to
develop new targeted treatments for the premutation dis-
orders. As an outgrowth of the meeting, papers were soli-
cited from the conference attendees such that groups of
scientists and clinicians would develop works that broadlyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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represent that effort.
Clinical involvement in carriers of premutation alleles
Only in the past decade has there been a general recog-
nition that premutation alleles are associated with clin-
ical involvement, although even prior to the discovery of
the FMR1 gene in 1991, Cronister and colleagues [1]
had reported a much higher incidence of early ovarian
failure (before the age of 40 years) in female premutation
carriers (approximately 20%) than in the general popula-
tion (approximately 1%). With the discovery of the FMR1
gene came the understanding that the women whose chil-
dren had FXS were carriers of ‘premutation’ alleles in
which a CGG-repeat element was unstable, with a propen-
sity for expansion to the full mutation. One exciting devel-
opment by Yrigollen et al. (2014 this issue), which was
presented at the meeting and is described in this special
edition, is the discovery that the presence and number of
AGG interruptions within the CGG repeat can have a pro-
found effect on the propensity for a premutation-to-full
mutation expansion during maternal transmission. Indeed,
a mother with approximately 70 to 80 CGG repeats and
no AGG interruptions has a greater than five-fold increase
in the probability of having a child with a full mutation al-
lele than a mother with the same number of CGG repeats
and two AGG interruptions. Thus, although the total
number of the CGG repeats is still the best predictor of
expansion to a full mutation, the number of AGG inter-
ruptions must also be considered when estimating the risk
of transmission of the premutation allele to a full muta-
tion. Interestingly, the maternal age also appears to con-
tribute to the risk of expansion.
A major theme of the meeting was the expanding
range of clinical features associated with the premuta-
tion allele. Discussion on this theme occurred at two
levels: first, the nature and extent of the associated phe-
notypes including the complexities of eliminating a bias
in clinical populations, and, second, how or whether the
definitions of the existing premutation disorders (for ex-
ample, FXTAS) will need to be changed in light of newer
findings; no clear consensus was reached on this latter
issue. The subject of premutation-associated clinical fea-
tures is addressed in this edition by the review by Wheeler
et al. (2014 this issue), which addresses the evidence of
increased risk for medical, psychiatric, and cognitive fea-
tures, specifically in women, and conditions that are now
known to be associated with premutation carrier status.
Although women generally have less severe problems asso-
ciated with FXTAS, they clearly have more reproductive/
ovarian problems, immune mediated problems and psychi-
atric problems and the reasons, are addressed by Wheeler
and colleagues. In this review, each feature is considered
according to the strength of its statistical associationwith premutation allele status, and, furthermore, areas
where there is a need for more research are proposed. In
keeping with this theme, Grigsby et al. (2014 this issue)
have summarized what is known about the cognitive/
neuropsychological phenotype of premutation carriers,
both before the onset of FXTAS and concomitant with
FXTAS.
Incomplete penetrance is another important concept
that was addressed at the meeting, one that is broadly
applicable to all of the main clinical phenotypes associ-
ated with premutation alleles. For example, of those who
are premutation carriers, only approximately 10 to 15% of
children who have the premutation will suffer seizures, ap-
proximately 20% of women will experience primary ovar-
ian insufficiency, and approximately half of older adult
men will develop FXTAS. This incomplete penetrance
across the phenotypic spectrum may be due to a combin-
ation of permissive/restrictive genetic backgrounds, as well
as various exogenous factors that would increase the likeli-
hood of clinical involvement. In the paper by Lozano et al.
(2014 this issue), this phenotypic variability is addressed
though a preliminary analysis of a ‘second (genetic) hit’
hypothesis and a developmental brain dysfunction model,
by considering the influence of copy number variation
(CNV) within additional genetic loci. Among 56 premuta-
tion carriers, the authors found rare CNVs (not found in
approximately 8,000 controls) in about one quarter of
their cases, and noted that the CNVs were more com-
monly identified in individuals with neurological in-
volvement. The authors suggest that further studies are
necessary to determine the frequency of second genetic
hits in individuals with the FMR1 premutation, and that
such information would increase our understanding of the
partial penetrance issue and the expression of a more se-
vere phenotype when additional genetic hits are found.
Neurodevelopmental problems in infants with the
premutation
Along with the increasing recognition of defined clin-
ical phenotypes in adult premutation carriers is a grow-
ing awareness of neurodevelopmental problems in early
childhood; however, such features remain woefully under-
recognized. Boys have higher rates of attention deficit
hyperactivity disorder (ADHD), shyness, social deficits,
autism spectrum disorder (ASD) and, less commonly, in-
tellectual disability (ID) [2]. Importantly, emerging data
from newborn screening studies presented at the inter-
national conference, indicates that some patterns of differ-
ences in developmental trajectories are present as early as
24 months in premutation carriers. In addition, in their
paper on visual motion processing deficits in infants with
the premutation presented in this edition, Rivera et al.
(2014 this issue) examined whether low-level visual pro-
cessing deficits in infants with FXS would also be present
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detection task, the authors found that the contrast levels
needed for detection of motion by the premutation infants
were significantly greater than those of typically develop-
ing infants, thus demonstrating an intrinsic early deficit
caused by the premutation. Further studies of these pro-
cessing deficits will lead to early treatment and a better
understanding of the relationship between early deficits
and the adult-onset premutation phenotypes.
Fragile X-associated primary ovarian insufficiency
Another phenotype discussed at the meeting was fragile
X-associated primary ovarian insufficiency (FXPOI), one
of the least studied disorders, due in part to the difficulty
in establishing the appropriate molecular and cellular
models. In a paper by the leaders in this field, Sherman
et al. (2014 this issue) outline the difficulties associated
with this area of research, which requires a detailed un-
derstanding of the role(s) of FMR1 mRNA and protein
(FMRP) on ovarian function. Moreover, since properly
understanding ovarian function also requires knowledge
of any associated hypothalamic and/or pituitary dysfunc-
tion, suitable models are difficult to establish, and, as
pointed out by the authors, non-invasive methods are
not available in humans. Fortunately, rodent and Dros-
ophila models have shed light on the question of ovarian
dysfunction. Sherman et al. review the current state of
understanding of the ovarian dysfunction associated with
the premutation, and discuss possible molecular disease
mechanisms leading to FXPOI.
Fragile X-associated tremor/ataxia syndrome
FXTAS was first described in 2001 [3] as a progressive
neurological disorder, with core features of intention
tremor and gait ataxia, affecting mainly older adult, pre-
mutation carrier males. However, since that time, the list
of known features associated with FXTAS (for example,
neuropathy, dysautonomia, Parkinsonism, cognitive de-
cline, and sleep apnea, among others) has grown steadily.
An important issue raised at the meeting was whether, or
to what extent, the definition of FXTAS should be allowed
to expand. In their paper on this topic, Hall et al. (2014
this issue) discuss the possible expanded definitions of
FXTAS, the classification of the related cognitive disorders,
and the FXTAS phenotype and associated features in
women. The authors also describe the first clinical trial for
FXTAS, an exciting undertaking given the fact that FXTAS
was only identified as a disorder thirteen years ago.
Slightly before the clinical description of FXTAS in
2001, Tassone and collaborators [4] made the observation
that the premutation alleles of the FMR1 gene produce far
more mRNA than do normal FMR1 alleles. The basis for
this excess transcriptional activity is not known at present;
however, the presence of elevated levels of the expandedCGG-repeat mRNA has led to the RNA toxicity hypoth-
esis, which is presumed to arise as a consequence of the
presence of excess, expanded CGG-repeat mRNA [5].
This segment of the meeting and a discussion about the
potential molecular mechanisms involved in the patho-
genesis of FXTAS are summarized by Charlet-Berguerand
et al. (2014 this issue). The leading model for toxicity
envisions that the CGG repeat sequesters one or more
proteins, thus reducing their ability to carry out their
normal tasks. One attractive candidate for sequestra-
tion is the DiGeorge syndrome critical region 8 protein
(DGCR8), which, with its binding partner, DROSHA, pro-
cesses miRNA precursors in the nucleus. Sequestration
of DGCR8 is proposed to result in the reduced pro-
duction of multiple miRNAs. However, there are other
models for toxicity that are just emerging, including a
proposed mechanism in which the mRNA is translated
from non-canonical upstream start sites, and which pro-
duces polyglycine stretches in the N-terminal portion of
the protein products. In addition, an antisense FMR1
mRNA and a number of long noncoding RNAs have been
identified within/near the FMR1 gene, although their
potential contribution to the clinical involvement ob-
served in premutation carriers is currently unknown. The
authors discuss the latest advances in our understanding
of the pathogenesis of FXTAS and emphasize the com-
plexity of the multiple molecular mechanisms that may
be involved.
Finally, as with FXPOI, there is a critical need for ani-
mal models that faithfully recapitulate the mechanisms
and phenotypes of FXTAS. Berman et al. (2014 this issue)
describe mouse models that have been quite useful in
explaining many of the features of FXTAS, or more prop-
erly, the premutation, since the mice do not manifest the
degree of neurodegeneration that is seen in humans. The
mouse models nevertheless do show much of the path-
ology seen in individuals with FXTAS (elevated mRNA,
intranuclear inclusions, slightly reduced FMRP). The mice
show abnormalities in dendritic and spine morphology -
remarkably - even in the neonatal period. Moreover,
the mice display impaired motor performance and neu-
rocognitive deficits in spatial and temporal memory pro-
cesses. The authors also discuss the use of the mouse
models for preclinical development of targeted therapies
for FXTAS.
Overall, bringing together professionals with different
expertise for this highly focused conference has ad-
vanced our understanding of the clinical phenotypes and
the molecular pathophysiology associated with premuta-
tion expansions of the FMR1 gene. The articles in this
special issue, as an outgrowth of the meeting, will help
to disseminate current knowledge so that the breadth of
premutation involvement is no longer considered to just
be FXTAS and FXPOI. Instead, a number of clinical
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X family, but may not be well known to the clinician, may
now be recognized as premutation clinical involvement.
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